300841 康华生物
交易中 08-16 11:18:24
资讯
新帖
简况
【企业动态】康华生物新增1件法院诉讼，案由为申请确认仲裁协议效力
证券之星 · 08-07
【企业动态】康华生物新增1件法院诉讼，案由为申请确认仲裁协议效力
康华生物(300841.SZ)累计回购比例达2.61% 耗资1.86亿元
智通财经 · 08-01
康华生物(300841.SZ)累计回购比例达2.61% 耗资1.86亿元
7月31日康华生物涨6.16%，中信建投中证1000指数增强A基金重仓该股
证券之星 · 07-31
7月31日康华生物涨6.16%，中信建投中证1000指数增强A基金重仓该股
康华生物涨6.16%，中泰证券二个月前给出“买入”评级
证券之星 · 07-31
康华生物涨6.16%，中泰证券二个月前给出“买入”评级
康华生物最新公告：近日取得1项发明专利证书
证券之星 · 07-25
康华生物最新公告：近日取得1项发明专利证书
康华生物最新公告：取得发明专利证书
证券之星 · 07-23
康华生物最新公告：取得发明专利证书
康华生物：截止2024年一季度末，公司前十位股东无参与转融通情况，具体情况可查阅公司定期报告
证券之星 · 07-22
康华生物：截止2024年一季度末，公司前十位股东无参与转融通情况，具体情况可查阅公司定期报告
更新版 1-HilleVax 将停止开发婴儿诺如病毒疫苗；股价大跌
Reuters · 07-08
更新版 1-HilleVax 将停止开发婴儿诺如病毒疫苗；股价大跌
康华生物获得实用新型专利授权：“一种清洗消毒装置”
证券之星 · 07-06
康华生物获得实用新型专利授权：“一种清洗消毒装置”
康华生物(300841.SZ)已耗资1.44亿元回购2%股份
智通财经 · 07-04
康华生物(300841.SZ)已耗资1.44亿元回购2%股份
康华生物(300841.SZ)累计回购1.57%股份 耗资1.14亿元
智通财经 · 07-01
康华生物(300841.SZ)累计回购1.57%股份 耗资1.14亿元
康华生物(300841.SZ)累计回购1%股份 耗资7333.36万元
智通财经 · 06-17
康华生物(300841.SZ)累计回购1%股份 耗资7333.36万元
康华生物：目前处于药品生产许可补充申报阶段，公司将全力推进上述项目生产许可的取得
证券之星 · 06-07
康华生物：目前处于药品生产许可补充申报阶段，公司将全力推进上述项目生产许可的取得
康华生物(300841.SZ)累计回购115万股 耗资6243.26万元
智通财经 · 06-04
康华生物(300841.SZ)累计回购115万股 耗资6243.26万元
康华生物：在接种狂犬疫苗后，抗体出现最早时间一般在第1剂疫苗注射后的7-14天
证券之星 · 05-29
康华生物：在接种狂犬疫苗后，抗体出现最早时间一般在第1剂疫苗注射后的7-14天
天风证券：给予康华生物买入评级
证券之星 · 05-27
天风证券：给予康华生物买入评级
康华生物：动保业务目前是我们一个培育中的业务，我们正持续关注宠物医药板块
证券之星 · 05-24
康华生物：动保业务目前是我们一个培育中的业务，我们正持续关注宠物医药板块
康华生物（300841）股东王振滔质押569.25万股，占总股本4.23%
证券之星 · 05-22
康华生物（300841）股东王振滔质押569.25万股，占总股本4.23%
康华生物最新公告：实际控制人收到行政处罚决定书
证券之星 · 05-16
康华生物最新公告：实际控制人收到行政处罚决定书
康华生物（300841）股东奥康集团有限公司质押225.5万股，占总股本1.67%
证券之星 · 05-09
康华生物（300841）股东奥康集团有限公司质押225.5万股，占总股本1.67%
公司概况
公司名称：
成都康华生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-16
主营业务：
成都康华生物制品股份有限公司的主营业务是冻干人用狂犬病疫苗（人二倍体细胞）和ACYW135群脑膜炎球菌多糖疫苗生产和销售及其他疫苗的研发。公司产品包括冻干人用狂犬病疫苗（人二倍体细胞）和ACYW135群脑膜炎球菌多糖疫苗。公司系高新技术企业，被授予“博士后创新实践基地”、“四川省诚信企业”等荣誉称号。
发行价格：
70.37
{"stockData":{"symbol":"300841","market":"SZ","secType":"STK","nameCN":"康华生物","latestPrice":53.29,"timestamp":1723778304000,"preClose":53.3,"halted":0,"volume":877100,"delay":0,"floatShares":122000000,"shares":135000000,"eps":4.1106,"marketStatus":"交易中","marketStatusCode":2,"change":-0.01,"latestTime":"08-16 11:18:24","open":52.91,"high":53.59,"low":52.32,"amount":46406000,"amplitude":0.0238,"askPrice":53.31,"askSize":17,"bidPrice":53.29,"bidSize":1,"shortable":0,"etf":0,"ttmEps":4.1106,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1723779000000},"adr":0,"adjPreClose":53.3,"symbolType":"stock","openAndCloseTimeList":[[1723771800000,1723779000000],[1723784400000,1723791600000]],"highLimit":58.63,"lowLimit":47.97,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":134650449,"pbRate":1.99,"roa":"--","roe":"4.16%","epsLYR":3.8073,"committee":0.188119,"marketValue":7176000000,"floatMarketCap":6514000000,"peRate":12.964044,"changeRate":-0.0002,"turnoverRate":0.0072,"status":1},"requestUrl":"/m/hq/s/300841/wiki","defaultTab":"wiki","newsList":[{"id":"2457835889","title":"【企业动态】康华生物新增1件法院诉讼，案由为申请确认仲裁协议效力","url":"https://stock-news.laohu8.com/highlight/detail?id=2457835889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457835889?lang=zh_cn&edition=full","pubTime":"2024-08-07 06:40","pubTimestamp":1722984021,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，7月29日康华生物（300841）新增1件法院诉讼如下：案号：（2024）川01民特669号法院：四川省成都市中级人民法院案由：申请确认仲裁协议效力申请人：上海一曜生物技术集团有限公司被申请人：成都康华生物制品股份有限公司案件类型：民事立案日期：2024年7月29日数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080700012462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"gpt_icon":0},{"id":"2456484246","title":"康华生物(300841.SZ)累计回购比例达2.61% 耗资1.86亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456484246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456484246?lang=zh_cn&edition=full","pubTime":"2024-08-01 20:40","pubTimestamp":1722516040,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康华生物(300841.SZ)公告，截至2024年7月31日，公司通过股票回购专用证券账户以集中竞价交易方式累计回购公司股份351.37万股，占公司目前总股本的比例为2.61%，最高成交价为63.26元/股，最低成交价为45.97元/股，成交总金额为1.86亿元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1158984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300841"],"gpt_icon":0},{"id":"2455906416","title":"7月31日康华生物涨6.16%，中信建投中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455906416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455906416?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:50","pubTimestamp":1722415846,"startTime":"0","endTime":"0","summary":"证券之星消息，7月31日康华生物涨6.16%，收盘报53.11元，换手率1.92%，成交量2.35万手，成交额1.22亿元。融资融券方面近5日融资净流入37.71万，融资余额增加；融券净流入1600.0，融券余额增加。根据2024基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为中信建投中证1000指数增强A。中信建投中证1000指数增强A目前规模为2.45亿元，最新净值0.8192，较上一交易日上涨0.21%，近一年下跌19.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601066","BK0239","000852.SH","000001.SH","399852","300841","BK0276","159845"],"gpt_icon":0},{"id":"2455290625","title":"康华生物涨6.16%，中泰证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2455290625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455290625?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:50","pubTimestamp":1722415832,"startTime":"0","endTime":"0","summary":"今日康华生物涨6.16%，收盘报53.11元。2024年5月9日，中泰证券研究员祝嘉琦,张楠发布了对康华生物的研报《技术授权利润上扬，高端狂苗静待恢复》，该研报对康华生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为74.38%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的宋硕、朱奕彰、陈竹。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024073100034325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","600918"],"gpt_icon":0},{"id":"2454842538","title":"康华生物最新公告：近日取得1项发明专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2454842538","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454842538?lang=zh_cn&edition=full","pubTime":"2024-07-25 17:30","pubTimestamp":1721899828,"startTime":"0","endTime":"0","summary":"康华生物公告，公司于近日取得中华人民共和国国家知识产权局颁发的发明专利证书，发明专利名称：结核分枝杆菌多免疫原抗原、编码其的mRNA、应用。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072500037051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2453277081","title":"康华生物最新公告：取得发明专利证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453277081","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453277081?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:11","pubTimestamp":1721729488,"startTime":"0","endTime":"0","summary":"康华生物公告，公司于近日取得中华人民共和国国家知识产权局颁发的发明专利证书，发明专利名称：结核分枝杆菌多免疫原抗原、编码其的多核苷酸、应用，专利号：ZL 2024 1 0459560.7。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300034888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"gpt_icon":0},{"id":"2453761503","title":"康华生物：截止2024年一季度末，公司前十位股东无参与转融通情况，具体情况可查阅公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2453761503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453761503?lang=zh_cn&edition=full","pubTime":"2024-07-22 20:00","pubTimestamp":1721649655,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物07月22日在投资者关系平台上答复投资者关心的问题。公司冻干人用狂犬病疫苗自2014年上市以来，随着产品优势逐步得到公众认可，客户数量持续增长。截止2024年一季度末，公司前十位股东无参与转融通情况，具体情况可查阅公司定期报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200028854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2449048597","title":"更新版 1-HilleVax 将停止开发婴儿诺如病毒疫苗；股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2449048597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449048597?lang=zh_cn&edition=full","pubTime":"2024-07-08 23:02","pubTimestamp":1720450974,"startTime":"0","endTime":"0","summary":" 路透7月8日 - 周一，HilleVax 股价暴跌87.6%，创下1.75美元的历史新低，因为这家生物技术公司表示将停止开发用于婴儿的诺如病毒候选疫苗。HilleVax 公司表示，它将停止 HIL-214 在婴儿中的进一步开发，并将探索是否能在成人中继续进行同样的开发。HilleVax于今年1月从成都康华生物制品 获得了HIL-216在大中华区以外的开发和商业化 。诺如病毒是导致呕吐、腹泻和其他食源性疾病的主要原因之一。目前，莫德纳 和 Vaxart 也在开发诺如病毒疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4551","BK0239","BK4534","VXRT","BK4585","BK4532","MRNA","BK4588","HLVX","BK4533","300841","BK4139","BK4548","BK4568"],"gpt_icon":0},{"id":"2449219144","title":"康华生物获得实用新型专利授权：“一种清洗消毒装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2449219144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449219144?lang=zh_cn&edition=full","pubTime":"2024-07-06 03:10","pubTimestamp":1720206621,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示康华生物新获得一项实用新型专利授权，专利名为“一种清洗消毒装置”，专利申请号为CN202322688513.3，授权日为2024年7月5日。今年以来康华生物新获得专利授权6个，与去年同期持平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070600003593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"gpt_icon":0},{"id":"2448417039","title":"康华生物(300841.SZ)已耗资1.44亿元回购2%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448417039","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448417039?lang=zh_cn&edition=full","pubTime":"2024-07-04 17:16","pubTimestamp":1720084594,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康华生物(300841.SZ)发布公告，截至2024年7月3日，公司通过股票回购专用证券账户以集中竞价交易方式累计回购公司股份269.40万股，占公司目前总股本的比例为2%，最高成交价为63.26元/股，最低成交价为45.97元/股，成交总金额为1.44亿元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1145623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2448955929","title":"康华生物(300841.SZ)累计回购1.57%股份 耗资1.14亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448955929","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448955929?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:11","pubTimestamp":1719832294,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康华生物(300841.SZ)公告，公司截至2024年6月30日累计回购公司股份211.76万股，占公司目前总股本的比例为1.57%，成交总金额为1.14亿元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2444151449","title":"康华生物(300841.SZ)累计回购1%股份 耗资7333.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444151449","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444151449?lang=zh_cn&edition=full","pubTime":"2024-06-17 17:36","pubTimestamp":1718617018,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康华生物(300841.SZ)公告，公司截至2024年6月14日以集中竞价交易方式累计回购公司股份134.66万股，占公司目前总股本的比例为1.00%，成交总金额为7333.36万元(不含交易费用)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1136219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2441301051","title":"康华生物：目前处于药品生产许可补充申报阶段，公司将全力推进上述项目生产许可的取得","url":"https://stock-news.laohu8.com/highlight/detail?id=2441301051","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2441301051?lang=zh_cn&edition=full","pubTime":"2024-06-07 19:01","pubTimestamp":1717758091,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物(300841)06月07日在投资者关系平台上答复投资者关心的问题。投资者：董秘你好，公司ACYW135群脑膜炎球菌多糖疫苗原液车间取得生产许可了吗？预计到什么时间能正常投产上市？康华生物董秘：尊敬的投资者您好，目前处于药品生产许可补充申报阶段，公司将全力推进上述项目生产许可的取得。感谢您的关注。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700040221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2440404274","title":"康华生物(300841.SZ)累计回购115万股 耗资6243.26万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2440404274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2440404274?lang=zh_cn&edition=full","pubTime":"2024-06-04 17:15","pubTimestamp":1717492500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康华生物(300841.SZ)公告，截至2024年5月31日，公司通过股票回购专用证券账户以集中竞价交易方式累计回购公司股份115万股，占公司目前总股本的比例为0.85%，最高成交价为63.26元/股，最低成交价为45.97元/股，成交总金额为6243.26万元(不含交易费用)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1130774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300841"],"gpt_icon":0},{"id":"2439154570","title":"康华生物：在接种狂犬疫苗后，抗体出现最早时间一般在第1剂疫苗注射后的7-14天","url":"https://stock-news.laohu8.com/highlight/detail?id=2439154570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439154570?lang=zh_cn&edition=full","pubTime":"2024-05-29 18:03","pubTimestamp":1716976995,"startTime":"0","endTime":"0","summary":"狂犬疫苗非要3-5针才有用？在接种狂犬疫苗后，抗体出现最早时间一般在第1剂疫苗注射后的7-14天。虽然首剂接种后的第14天可以产生抗体，但需经第4针或第5针接种，才能产生较持久的高滴度抗体。因为狂犬疫苗是灭活疫苗，需要多次接种才能完成整个免疫保护。目前，公司的冻干人用狂犬病疫苗采用经典接种程序5针法进行接种，作为国内首个上市的人二倍体狂犬病疫苗厂家，公司在工艺技术、品牌影响、市场渠道等方面具备优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052900035545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","300841"],"gpt_icon":0},{"id":"2438817950","title":"天风证券：给予康华生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2438817950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2438817950?lang=zh_cn&edition=full","pubTime":"2024-05-27 07:35","pubTimestamp":1716766516,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松近期对康华生物进行研究并发布了研究报告《2023年业绩增长稳健，人二倍体狂苗销售值得期待》，本报告对康华生物给出买入评级，当前股价为58.97元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级7家；过去90天内机构目标均价为86.45。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052700000257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","300841"],"gpt_icon":0},{"id":"2437080109","title":"康华生物：动保业务目前是我们一个培育中的业务，我们正持续关注宠物医药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2437080109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437080109?lang=zh_cn&edition=full","pubTime":"2024-05-24 19:01","pubTimestamp":1716548486,"startTime":"0","endTime":"0","summary":"动保业务目前是我们一个培育中的业务，我们正持续关注宠物医药板块。公司将全力推进康华生物疫苗生产扩建项目生产许可的取得，取得生产许可后，疫苗生产以及完工后通过批签发尚需经过一定的周期，我们将根据信息披露相关要求对该项目进展进行披露。目前该项目的竣工环境保护验收监测报告正按环境保护相关规定在相关平台进行公示。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400039752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","09939","BK1161","300841","BK0239","BK1574"],"gpt_icon":0},{"id":"2437295357","title":"康华生物（300841）股东王振滔质押569.25万股，占总股本4.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2437295357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437295357?lang=zh_cn&edition=full","pubTime":"2024-05-22 21:37","pubTimestamp":1716385049,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物5月22日公开信息显示，股东王振滔向温州银行股份有限公司永嘉支行合计质押569.25万股，占总股本4.23%。质押详情见下表：截止本公告日，股东奥康集团有限公司已累计质押股份1223.0万股，占其持股总数的75.01%，股东王振滔已累计质押股份1198.75万股，占其持股总数的85.6%。康华生物主营业务：疫苗研发、生产及销售业务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200039585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2435616670","title":"康华生物最新公告：实际控制人收到行政处罚决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435616670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2435616670?lang=zh_cn&edition=full","pubTime":"2024-05-16 21:10","pubTimestamp":1715865021,"startTime":"0","endTime":"0","summary":"康华生物公告，实际控制人、董事长王振滔收到行政处罚决定书。对王振滔给予警告，并处以300万元罚款，其中作为直接负责的主管人员处以100万元罚款，作为实际控制人处以200万元罚款。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600034088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"gpt_icon":0},{"id":"2434394018","title":"康华生物（300841）股东奥康集团有限公司质押225.5万股，占总股本1.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434394018","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2434394018?lang=zh_cn&edition=full","pubTime":"2024-05-09 21:35","pubTimestamp":1715261728,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物5月9日公开信息显示，股东奥康集团有限公司向南太湖(天津)商业保理有限公司合计质押225.5万股，占总股本1.67%。质押详情见下表：截止本公告日，股东奥康集团有限公司已累计质押股份1223.0万股，占其持股总数的75.01%，股东王振滔已累计质押股份1198.75万股，占其持股总数的85.6%。康华生物主营业务：疫苗研发、生产及销售业务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900040164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-16","address":"四川省成都市龙泉驿区经济技术开发区北京路182号","stockEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":0.0536},{"period":"3month","weight":-0.1353},{"period":"6month","weight":-0.0912},{"period":"1year","weight":-0.1142},{"period":"ytd","weight":-0.2912}],"companyName":"成都康华生物制品股份有限公司","boardCode":"AI0027","perCapita":"6398股","boardName":"医药制造业","registeredCapital":"13465万元","compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0877},{"period":"6month","weight":0.004},{"period":"1year","weight":-0.0866},{"period":"ytd","weight":-0.0328}],"survey":" 成都康华生物制品股份有限公司的主营业务是冻干人用狂犬病疫苗（人二倍体细胞）和ACYW135群脑膜炎球菌多糖疫苗生产和销售及其他疫苗的研发。公司产品包括冻干人用狂犬病疫苗（人二倍体细胞）和ACYW135群脑膜炎球菌多糖疫苗。公司系高新技术企业，被授予“博士后创新实践基地”、“四川省诚信企业”等荣誉称号。","serverTime":1723778308320,"listedPrice":70.37,"stockholders":"19104人(较上一季度增加3.81%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康华生物(300841)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康华生物(300841)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康华生物,300841,康华生物股票,康华生物股票老虎,康华生物股票老虎国际,康华生物行情,康华生物股票行情,康华生物股价,康华生物股市,康华生物股票价格,康华生物股票交易,康华生物股票购买,康华生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康华生物(300841)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康华生物(300841)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}